FCM
FOMX

Farallon Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Farallon Capital Management’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-170,900
Closed -$1.25M – 84
2015
Q3 		$1.25M Buy
170,900
+900
+0.5% +$9.17K 0.02% 80
2015
Q2 		$1.74M Buy
+170,000
New +$1.88M 0.02% 88

Other funds holding FOMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Farallon Capital Management's FOMX Position: Q4 2015 in Review

Farallon Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2015, closing a stake of 170,900 shares — an estimated $1.25M sold.

Farallon Capital Management first reported a position in FOMX in Q2 2015 and held it in 2 quarters. The position peaked at $1.74M in Q2 2015. 72 funds tracked by Wall St. Rank hold FOMX as of Q4 2015.

  • Farallon Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • Farallon Capital Management sold 170,900 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2015, an estimated $1.25M.
  • Farallon Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 2 quarters.
  • Farallon Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.74M in Q2 2015.
  • 72 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2015.

Based on Farallon Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.